Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Inozyme Pharma Inc stock (INZY)

Buy Inozyme Pharma Inc stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Inozyme Pharma Inc is a biotechnology business based in the US. Inozyme Pharma Inc shares (INZY) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.29 – a decrease of 10.44% over the previous week. Inozyme Pharma Inc employs 59 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Inozyme Pharma Inc stock

Top pick for advanced traders

Go to site
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

Our pick for transfer bonus

Go to site
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • Complimentary access to a financial planner and automated investing

How to buy Inozyme Pharma Inc stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – INZY. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Inozyme Pharma Inc stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Name Product USFST Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
OPTO
Finder Score: 3.1 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $1,000 in stock
Zero-commission stocks, ETFs and options, with no options per-contract fees. Plus, a no-advisory-fee robo-advisor and complimentary access to financial planners.
Robinhood
Finder Score: 4.5 / 5: ★★★★★
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.5%
Get a free stock
Trade stocks, options, ETFs and crypto without commissions and on a user-friendly platform. Plus, a 1% IRA match and no options contract fees.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Inozyme Pharma Inc stock price (NASDAQ: INZY)

Use our graph to track the performance of INZY stocks over time.

Inozyme Pharma Inc shares at a glance

Information last updated 2024-11-01.
Latest market close$4.29
52-week range$2.71 - $7.80
50-day moving average $5.24
200-day moving average $5.20
Wall St. target price$19.00
PE ratio N/A
Dividend yield N/A
Earnings per share (TTM) $-1.44

Is it a good time to buy Inozyme Pharma Inc stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Inozyme Pharma Inc price performance over time

Historical closes compared with the close of $4.54 from 2024-10-30

1 week (2024-10-25) -5.22%
1 month (2024-10-01) -9.56%
3 months (2024-08-01) -16.08%
6 months (2024-05-01) -1.52%
1 year (2023-11-01) 57.09%
2 years (2022-10-31) 157.95%
3 years (2021-11-01) 10.3
5 years (2019-10-28) N/A

Inozyme Pharma Inc financials

Gross profit TTM $0
Return on assets TTM -37.87%
Return on equity TTM -88.56%
Profit margin 0%
Book value $1.52
Market Capitalization $305.3 million

TTM: trailing 12 months

Inozyme Pharma Inc share dividends

We're not expecting Inozyme Pharma Inc to pay a dividend over the next 12 months.

Inozyme Pharma Inc share price volatility

Over the last 12 months, Inozyme Pharma Inc's shares have ranged in value from as little as $2.71 up to $7.795. A popular way to gauge a stock's volatility is its "beta".

INZY.US volatility(beta: 1.51)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Inozyme Pharma Inc's is 1.51. This would suggest that Inozyme Pharma Inc's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Inozyme Pharma Inc overview

Inozyme Pharma, Inc. , a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. .

Frequently asked questions

null
What percentage of Inozyme Pharma Inc is owned by insiders or institutions?
Currently 0.517% of Inozyme Pharma Inc shares are held by insiders and 97.793% by institutions.
How many people work for Inozyme Pharma Inc?
Latest data suggests 59 work at Inozyme Pharma Inc.
When does the fiscal year end for Inozyme Pharma Inc?
Inozyme Pharma Inc's fiscal year ends in December.
Where is Inozyme Pharma Inc based?
Inozyme Pharma Inc's address is: 321 Summer Street, Boston, MA, United States, 02210
What is Inozyme Pharma Inc's ISIN number?
Inozyme Pharma Inc's international securities identification number is: US45790W1080

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site